GLP-1s and Sex Drive: What the Evidence Supports, and What It Does Not

The short version

Women ask this constantly and almost nobody answers it carefully. The honest position is that the direction of the effect is not settled, the mechanisms proposed run both ways, and most of what you will read confidently online is inference.

What follows is what exists, what it can and cannot support, and how to tell which of three very different things is happening to you.

What the research actually says

The most direct source is a 2026 narrative review in Sexual Medicine Reviews examining GLP-1 receptor agonists and sexual function in women and men. Its own subtitle is the finding: emerging evidence and the need for further research¹. It notes these drugs may influence reward-related and sexual behaviour — plausible, since GLP-1 receptors are involved in reward pathways — without that translating into a settled clinical picture.

Read that as a hypothesis worth taking seriously, not an answer.

Alongside it sits a much better-evidenced fact from a different setting: major weight loss changes sexual function. A systematic review and meta-analysis of female sexual dysfunction after bariatric surgery found measurable change². That is the closest analogue — a comparable change in body, hormones and self-perception, properly studied — and it is an analogue, not a study of these medicines.

The three-way confound, which is the actual problem

If desire changes on a GLP-1, at least three things could be responsible and they are almost impossible to separate in one person:

The drug. GLP-1 receptors sit in reward circuitry. If a medicine dampens the wanting of food, asking whether it dampens other wanting is a reasonable question. Reasonable is not the same as demonstrated.

The weight loss. Independent of any drug, losing a substantial amount of weight changes hormones, body image and energy — sometimes toward more desire, sometimes less.

The life around it. Nausea in the first months. Poor sleep. A relationship renegotiating itself. None of that is pharmacology, and all of it affects a sex life.

A study that could separate these would need to compare GLP-1 users against people losing similar weight by other means, measuring the same instruments over time. That study has not been done.

How to tell which one you are in

Not a diagnosis — a way to think about it:

• Desire is down but arousal works normally when you get there. More often the weight-loss-and-life pattern than a drug effect.
• Physical dryness or discomfort is the barrier, not interest. That points at tissue and oestrogen, not desire — and it is treatable in its own right, which is the practical difference. See the cycle and reproductive-hormone evidence.
• Everything is flat, including things unrelated to sex. Worth asking about mood rather than libido, particularly alongside an antidepressant — see GLP-1s and antidepressants.
• It arrived exactly with the nausea and left with it. That is tolerability, and it usually settles once the dose stops climbing.

What I would tell a clinician

That distinction — desire versus arousal versus discomfort — is the single most useful thing you can bring to an appointment, because the three lead to entirely different conversations. "My libido is down" gets a shrug more often than it should. "Desire is unchanged but it is physically uncomfortable" gets a treatment.

Where this sits on the evidence scale

Low. One narrative review calling for more research, an analogue literature from bariatric surgery, and a mechanism that is biologically plausible and clinically unproven.

I would rather publish that sentence than a confident answer, because a confident answer here would be invented. If a good comparative study lands, this page changes.